Monday, July 21, 2008 - 11:00 a.m. ET; 8:00 a.m. PT
VANCOUVER and SAN DIEGO, CA, July 18 /CNW/ - MIGENIX Inc. (TSX: MGI;
OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will
host a conference call and webcast on Monday, July 21, 2008 at 11:00 a.m. ET
(8:00 a.m. PT) to discuss financial results for the fourth fiscal quarter and
fiscal year ended April 30, 2008 and provide an update on company activities.
To participate in the conference call, please dial 416-644-3416 or
The call will be available for replay until July 28, 2008 by calling
416-640-1917 or 1-877-289-8525 and entering the pass code 21278725 followed by
the pound sign. The live and archived webcast can be accessed through the
company's website at www.migenix.com for the next 90 days.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's programs include drug candidates for:
the prevention of catheter-related infections (Phase III), the treatment of
dermatological diseases (end of Phase II), the treatment of chronic
hepatitis C infections (Phase II and preclinical), the treatment of serious
gram positive bacterial infections (preclinical) and the treatment of
hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver,
British Columbia, Canada with US operations in San Diego, California.
Additional information can be found at www.migenix.com.
James M. DeMesa, M.D.
President & CEO
For further information:
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, email@example.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com